Bertram Jacobs
Bertram Jacobs, professor of virology in the School of Life Sciences and member of ASU-Banner Neurodegenerative Disease Research Center at the Biodesign Institute, received an award from the NIH’s National Institute of Allergy and Infectious Disease for a project titled, “Safer, More Effective Mpox/Smallpox Vaccine.”
Researchers have found that the monkeypox virus (MPXV) is unusual compared to related viruses because it is partly vulnerable to the body’s natural defense system, called type I interferon (IFN). This weakness happens because MPXV has a “broken” version of a protective protein (called F3L), which normally helps viruses hide from the immune system.
In vaccinia virus (VACV), the virus used in smallpox vaccines, this protective protein (E3) works properly, blocking the body from detecting the infection. But in MPXV, the protein is truncated (cut short), so it doesn’t fully work, leaving the virus exposed to immune attack.
The problem is that current vaccines contain the full version of this protective gene. That means, in theory, if someone with MPXV gets vaccinated, the vaccine virus could “repair” MPXV’s weak spot, helping it evade immune defenses again.
To study this, researchers plan to create a special mouse model of MPXV infection. They’ll test different MPXV strains and then evaluate a new type of vaccine. This vaccine is designed so it cannot fix MPXV’s broken gene, making it a potentially safer and more effective option.